| Literature DB >> 35159970 |
Sara Souto-Miranda1,2,3, Maria A Mendes4, João Cravo4, Lília Andrade4, Martijn A Spruit3,5, Alda Marques1.
Abstract
The 6 min walking test (6MWT) has been largely studied. Less is, however, known about responders and non-responders to pulmonary rehabilitation (PR) in other meaningful activities. We explored responders and non-responders and the predictors of response to PR in the 1 min sit-to-stand test (1 min STS) and the 6MWT and compared both measures in classifying responders. An observational study was conducted with 121 people with chronic obstructive pulmonary disease (COPD). The functional status was assessed before and after PR. Baseline differences between responders and non-responders were tested with Mann-Whitney U, chi-square, or Fisher exact tests. Predictors were explored with binary logistic regressions. Agreement between both measures was assessed with chi-square, Cohen's kappa, and McNemar tests. There were 54.5% and 57.0% of responders in the 1 min STS and the 6MWT, respectively. The proportion of responders was significantly different (p = 0.048), with a small agreement between the measures (kappa = 0.180; p = 0.048). The baseline 6MWT was the only significant predictor of response in the 6MWT (OR = 0.995; pseudo-r2 = 0.117; p < 0.001). No significant predictors were found for the 1 min STS. A large number of non-responders in terms of functional status exist. The 1 min STS and the 6MWT should not be used interchangeably. Future studies should explore the added benefit of personalizing PR to this outcome and investigate other potential predictors.Entities:
Keywords: COPD; functional status; pulmonary rehabilitation; responder analysis
Year: 2022 PMID: 35159970 PMCID: PMC8836346 DOI: 10.3390/jcm11030518
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Baseline characteristics and effects of pulmonary rehabilitation in people with chronic obstructive pulmonary disease (COPD) (n = 121).
| Baseline | Post | ∆ Pre-Post | Effect Size (d) | ||
|---|---|---|---|---|---|
| Age, years | 69.0 (65.0–75.0) | ||||
| Sex, | |||||
| Male | 99 (81.8) | ||||
| Female | 22 (18.2) | ||||
| BMI, kg/m2 | 26.4 ± 4.8 | 26.4 ± 4.6 | −0.0 ± 0.9 | 0.049 | 0.591 |
| Underweight, <21, | 13 (10.7) | 10 (8.3) | 3 (2.4) | <0.001 * | |
| Obese >30, | 28 (23.1) | 27 (22.5) | 1 (0.6) | ||
| Smoking status, | |||||
| Never | 22 (18.2) | ||||
| Former | 82 (67.8) | ||||
| Current | 17 (14.0) | ||||
| Pack-years | 31.2 (10.0–60.0) | ||||
| LTOT, | 12 (9.9) | ||||
| NIV, | 16 (13.2) | ||||
| CCI, score | 4.0 (3.0–5.0) | ||||
| FEV1 % predicted | 50.0 (37.0–63.7) | ||||
| GOLD grade, | |||||
| 1 | 9 (7.4) | ||||
| 2 | 52 (43.0) | ||||
| 3 | 47 (38.8) | ||||
| 4 | 13 (10.7) | ||||
| GOLD group, | |||||
| A | 32 (26.4) | ||||
| B | 66 (54.5) | ||||
| C | 3 (2.5) | ||||
| D | 20 (16.5) | ||||
| Respiratory-related hospital admissions in the previous 12 months, | 0.0 (0.0–0.0) | ||||
| AECOPD in the previous 12 months, | 0.0 (0.0–1.0) | ||||
| mMRC, score | 2.0 (1.0–3.0) | 1.0 (1.0–2.0) | 0.0 (−1.0–0.0) | 0.39 | <0.001 * |
| CAT score, points | 14.8 ± 8.0 | 12.1 ± 7.0 | −2.7 ± 5.8 | 0.46 | <0.001 * |
| SGRQ, total score | 45.1 ± 19.8 | 38.7 ± 19.1 | −6.4 ± 12.2 | 0.52 | <0.001 * |
| QVC, KgF | 30.6 ± 8.4 | 33.4 ± 10.2 | 2.7 ± 8.7 | 0.31 | <0.001 * |
| Handgrip strength, KgF | 34.3 ± 9.2 | 34.0 ± 10.1 | −0.3 ± 7.5 | 0.05 | 0.619 |
| BPAAT, score | 0.0 (0.0–3.0) | 4.0 (2.0–6.0) | 2.0 (1.0–4.0) | 0.69 | <0.001 * |
| Brief-BESTest | 19.0 (15.0–22.0) | 21.0 (18.0–24.0) | 2.0 (0.0–4.0) | 0.63 | <0.001 * |
| 1 min STS, repetitions | 23.0 (18.0–29.0) | 27.0 (21.0–33.0) | 3.0 (0.0–6.0) | 0.58 | <0.001 * |
| 1 min STS <70% predicted, | 59 (48.8) | 38 (31.4) | 21 (17.4) | <0.001 * | |
| 6MWD, m | 419.6 (331.9–508.6) | 465.0 (386.7–540.3) | 41.0 (7.0–75.3) | 0.56 | <0.001 * |
| 6MWD < 70% predicted, | 27 (22.3) | 20 (16.5) | 7 (5.8) | <0.001 * |
BMI: body mass index; LTOT: long-term oxygen therapy; NIV: non-invasive ventilation; CCI: Charlson comorbidity index; FEV1: forced expiratory volume in the first second; GOLD: global initiative for chronic obstructive lung disease. 1–4: Severity of airflow limitation, 1—FEV1 ≥ 80% predicted, 2—50% ≤ FEV1 < 80% predicted, 3—30% ≤ FEV1 < 50% predicted, and 4—FEV1 < 30% predicted. CAT: COPD assessment test; A–D: A—CAT < 10 points and 0–1 moderate-to-severe exacerbations (not leading to hospitalization), B—CAT ≥ 10 points and 0–1 moderate-to-severe exacerbations (not leading to hospitalization), C—CAT < 10 points and ≥2 moderate-to-severe exacerbations or ≥1 moderate-to-severe exacerbations leading to hospitalization, and D—CAT ≥ 10 points and ≥2 moderate-to-severe exacerbations or ≥1 moderate-to-severe exacerbations leading to hospitalization; AECOPD: acute exacerbations of COPD; mMRC: modified medical research council dyspnea scale; SGRQ: Saint George’s respiratory questionnaire; QVC: quadriceps voluntary contraction; BPAAT: brief physical activity assessment tool; Brief-BESTest: brief-balance evaluation system test; 1 min STS: 1 min sit-to-stand test; 6MWD: 6 min walking distance. ∆ represents the mean or median difference according to data distribution. * Statistically significant difference.
Baseline differences between responders and non-responders in terms of pulmonary rehabilitation of people with chronic obstructive pulmonary disease (COPD) in the 1 min sit-to-stand test and the 6 min walking test (n = 121).
| 1-Min STS | 6MWT | 1-Min STS and 6MWT | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Responders ( | Non-Responders ( | Responders ( | Non-Responders ( | Responders in Both Measures ( | Non-Responders in Both Measures ( | ||||
| Age, years | 69.0 (64.0–75.0) | 70.0 (67.5–74.5) | 0.150 | 69.0 (65.0–71.5) | 69.0 (65.0–71.5) | 0.344 | 69.0 (61.5–73.0) | 70.0 (66.0–75.0) | 0.178 |
| Sex, | |||||||||
| Male | 50 (75.8) | 49 (89.1) | 0.058 | 57 (82.6) | 42 (80.8) | 0.795 | 34 (79.1) | 65 (83.3) | 0.561 |
| Female | 16 (24.2) | 6 (10.9) | 12 (17.4) | 10 (19.2) | 9 (20.9) | 13 (16.7) | |||
| BMI, kg/m2 | 27.0 (24.3–30.1) | 24.2 (22.1–28.3) | 0.008 | 27.0 ± 4.6 | 25.7 ± 5.0 | 0.143 | 27.5 (25.0–30.2) | 24.6 (22.4–28.6) | 0.009 |
| Smoking status, | |||||||||
| Never | 13 (19.7) | 9 (16.4) | 0.475 | 11 (15.9) | 11 (21.2) | 0.668 | 6 (14.0) | 16 (20.5) | 0.504 |
| Former | 46 (69.7) | 36 (65.5) | 49 (71.0) | 33 (63.5) | 32 (74.4) | 50 (64.1) | |||
| Current | 7 (10.6) | 10 (18.2) | 9 (13.0) | 8 (15.4) | 5 (11.6) | 12 (15.4) | |||
| Pack-years, | 38.8 (12.3–64.0) | 30.0 (6.1–55.0) | 0.342 | 34.1 (13.1–60.0) | 28.5 (3.2–69−0) | 0.756 | 38.8 (17.0–60.0) | 30.0 (5.9–60.8) | 0.510 |
| LTOT, | 8 (12.1) | 4 (7.3) | 0.374 | 6 (8.7) | 6 (11.5) | 0.605 | 4 (9.3) | 8 (10.3) | 0.867 |
| NIV, | 11 (16.7) | 5 (9.1) | 0.221 | 11 (15.9) | 5 (9.6) | 0.309 | 9 (20.9) | 7 (9.0) | 0.063 |
| CCI, score | 4.0 (3.0–5.0) | 4.0 (3.0–5.0) | 0.513 | 4.0 (3.0–5.0) | 4.0 (3.0–4.5) | 0.313 | 4.0 (3.0–5.0) | 4.0 (3.0–5.0) | 0.980 |
| FEV1, % predicted | 54.3 ± 17.0 | 47.8 ± 18.4 | 0.049 | 50.4 ± 16.0 | 52.6 ± 20.3 | 0.521 | 54.0 (41.0–63.0) | 47.0 (36.0–63.7) | 0.273 |
| GOLD grade, | |||||||||
| 1 | 6 (9.1) | 3 (5.5) | 0.054 | 3 (4.3) | 6 (11.5) | 0.180 | 2 (4.7) | 7 (9.0) | 0.064 |
| 2 | 33 (50.0) | 19 (34.5) | 33 (47.8) | 19 (36.5) | 25 (58.1) | 27 (34.6) | |||
| 3 | 24 (36.4) | 23 (41.8) | 28 (40.6) | 19 (36.5) | 14 (32.6) | 33 (42.3) | |||
| 4 | 3 (4.5) | 10 (18.2) | 5 (7.2) | 8 (15.4) | 2 (4.7) | 11 (14.1) | |||
| GOLD group, | |||||||||
| A | 14 (21.2) | 18 (32.7) | 0.525 | 16 (23.2) | 16 (30.8) | 0.405 | 9 (20.9) | 23 (29.5) | 0.375 |
| B | 39 (59.1) | 27 (49.1) | 42 (60.9) | 24 (46.2) | 28 (65.1) | 38 (48.7) | |||
| C | 2 (3.0) | 1 (1.8) | 1 (1.4) | 2 (3.8) | 1 (2.3) | 2 (2.6) | |||
| D | 11 (16.7) | 9 (16.4) | 10 (14.5) | 10 (19.2) | 5 (11.6) | 15 (19.2) | |||
| Respiratory-related hospital admissions in the previous 12 months, | 0.0 (0.0–0.0) | 0.0 (0.0–0.0) | 0.775 | 0.0 (0.0–0.0) | 0.0 (0.0–0.0) | 0.298 | 0.0 (0.0–0.0) | 0.0 (0.0–0.0) | 0.455 |
| AECOPD in the previous 12 months, | 0.0 (0.0–1.0) | 0.0 (0.0–1.0) | 0.083 | 0.0 (0.0–1.0) | 0.0 (0.0–1.0) | 0.983 | 0.0 (0.0–1.0) | 0.0 (0.0–1.0) | 0.399 |
| mMRC, score | 2.0 (1.0–3.0) | 2.0 (1.0–3.0) | 0.441 | 2.0 (1.0–3.0) | 2.0 (1.0–3.0) | 0.679 | 2.0 (1.0–2.5) | 2.0 (1.0–3.0) | 0.420 |
| CAT, total score | 15.9 ± 8.2 | 13.4 ± 7.5 | 0.078 | 15.5 ± 7.9 | 13.8 ± 8.0 | 0.228 | 13.2 ± 7.8 | 14.4 ± 8.0 | 0.425 |
| SGRQ, total score | 53.7 (30.2–62.8) | 43.1 (30.1–53.5) | 0.060 | 52.6 (30.1–61.8) | 45.1 (30.2–56.9) | 0.321 | 53.7 (29.6–61.1) | 45.1 (30.2–57.4) | 0.399 |
| QVC, KgF | 30.2 ± 8.6 | 31.0 ± 8.2 | 0.561 | 30.7 ± 8.9 | 30.4 ± 7.7 | 0.875 | 30.1 ± 9.1 | 30.8 ± 8.0 | 0.679 |
| Handgrip strength, KgF | 34.3 ± 10.4 | 34.4 ± 7.7 | 0.924 | 34.3 ± 9.9 | 34.3 ± 8.4 | 0.987 | 34.6 ± 10.5 | 34.2 ± 8.5 | 0.803 |
| BPAAT, score | 0.0 (0.0–3.0) | 1.0 (0.0–3.0) | 0.513 | 0.0 (0.0–2.0) | 1.0 (0.0–4.0) | 0.038 | 0.0 (0.0–1.0) | 0.5 (0.0–3.0) | 0.156 |
| Brief-BESTest, score | 19.0 (14.0–22.0) | 18.0 (16.0–22.0) | 0.876 | 18.0 (15.0–22.0) | 19.0 (16.0–22.0) | 0.373 | 19.0 (13.5–22.0) | 18.0 (16.0–22.0) | 0.580 |
| 1 min STS, repetitions | 22.5 (18.0–27.0) | 25.0 (20.5–31.0) | 0.035 | 22.0 (18.0–28.0) | 25.5 (20.0–31.5) | 0.113 | 22.0 (17.5–26.5) | 24.5 (20.0–30.0) | 0.041 |
| 1 min STS <70% predicted, | 37 (56.1) | 22 (40.0) | 0.078 | 37 (53.6) | 22 (42.3) | 0.218 | 28 (65.1) | 31 (39.7) | 0.008 |
| 6MWD, m | 404.4 ± 135.2 | 419.2 ± 115.9 | 0.524 | 390.0 (295.0–480.0) | 489.2 (363.2–534.5) | <0.001 | 386.4 (287.4–478.1) | 441.3 (356.2–523.5) | 0.042 |
| 6MWD <70% predicted, | 17 (25.8) | 10 (18.2) | 0.319 | 21 (30.4) | 6 (11.5) | 0.013 | 15 (34.9) | 12 (15.4) | 0.014 |
BMI: body mass index; LTOT: long-term oxygen therapy; NIV: non-invasive ventilation; CCI: Charlson comorbidity index; FEV1: forced expiratory volume in 1 s; GOLD: global initiative for chronic obstructive lung disease. 1–4: Severity of airflow limitation, 1—FEV1 ≥ 80% predicted, 2—50% ≤ FEV1 < 80% predicted, 3—30% ≤ FEV1 < 50% predicted, and 4—FEV1 < 30% predicted. CAT: COPD assessment test; A–D: A—CAT < 10 points and 0–1 moderate-to-severe exacerbations (not leading to hospitalization), B—CAT ≥ 10 points and 0–1 moderate-to-severe exacerbations (not leading to hospitalization), C—CAT < 10 points and ≥2 moderate-to-severe exacerbations or ≥1 moderate-to-severe exacerbations leading to hospitalization, and D—CAT ≥ 10 points and ≥2 moderate-to-severe exacerbations or ≥1 moderate-to-severe exacerbations leading to hospitalization; AECOPD: acute exacerbations of COPD; mMRC: modified medical research council dyspnea scale; SGRQ: Saint George’s respiratory questionnaire; QVC: quadriceps voluntary contraction; BPAAT: brief physical activity assessment tool; Brief-BESTest: brief-balance evaluation systems test; 1 min STS: 1 min sit-to-stand test; 6MWD: 6 min walking distance.
Figure 1Scatter plot of responders and non-responders to community-based pulmonary rehabilitation of people with chronic obstructive pulmonary disease (COPD) with the mean difference achieved in the 6 min walking test (X-axis) and the 1 -min sit-to-stand test (Y-axis). The axes are intersected at minimal clinically important differences, 6MWT: 30 m and 1 min STS: 3 repetitions. 1 min STS: 1 min sit-to-stand test; 6MWT: 6 min walking test.